glp-1 medication providers with patient support Insurance companies scrambling to need for drugs - The C.O.R.E. Group Start the New Year with

GHK-Cu may support healthier extracellular matrix balance

Semaglutide has FDA approval and over 100,000 patient-years of clinical safety data from Phase III trials and post-market surveillance, with well-characterized side effects (nausea in 3045%, serious adverse events like pancreatitis in fewer than 0.5%)

Adjusting the inhaler technique or switching to a different device may help reduce these symptoms

Safety profiles remain based on short-term animal studies rather than lifelong human observation

Sleep Disruption Nausea, reflux, and delayed stomach emptying can affect sleep quality, especially early in treatment